Treatment News : Head-and-Neck Cancer Treatment Works Just as Well in People With HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 21, 2011

Head-and-Neck Cancer Treatment Works Just as Well in People With HIV

Standard radiation treatment for head-and-neck cancer is just as effective and safe in people with HIV as in their HIV-negative counterparts, according to a small study published in the January issue of the International Journal of Radiation Oncology • Biology • Physics. These data answer concerns that treatment for head-and-neck cancers could potentially be riskier for HIV-positive people.

Though the rates of many types of cancer have diminished significantly in people with HIV since the introduction of potent antiretroviral (ARV) therapy in the late 1990s, several types of cancer are on the rise, including those affecting the head and neck. To date, cancer specialists have been concerned about using the standard treatment for these types of cancer—which include tumors in the oral cavity and throat, such as those caused by human papillomavirus (HPV) and tobacco use—often involving high doses of radiation treatment in people with HIV.

The concern is that people with HIV face a greater risk of immediate and long-term side effects from such treatment and that a person’s survival and health could be compromised. Such concerns are especially prominent for people who receive both radiation and chemotherapy, and have been born out by a few very small studies.

To explore this issue, Allen Chen, MD, and his colleagues at the University of California at Davis studied the medical records of 12 HIV-positive people who underwent radiation therapy for head and neck cancer.

Contrary to previous concerns, people with HIV faired just as well in this study as HIV-negative people did in other studies. The three-year survival rate was 78 percent, and local control of the cancer was 92 percent. While 58 percent of the people did experience a serious side effect, including swelling and tissue damage where the radiation was focused, this rate was no higher than the risk found in HIV-negative people.

People receiving both radiation and chemotherapy did see their CD4 cells drop—from an average of about 600 to 200—however, none required additional treatment to increase their white blood cells, and all saw their CD4 counts rebound after treatment was completed.

The authors note that nine of the 12 patients in this study were taking ARV therapy while being treated for cancer. Previous studies have shown that concomitant use of ARVs while undergoing cancer treatment is associated with improved immunologic and clinical outcomes.

All of the participants also received antibiotics and had feeding tubes inserted as preventive measures against oral infections—common occurrences in people undergoing radiation therapy for head-and-neck cancers. These measures, the authors note, could have contributed to the positive outcomes noted in the study, and they differ from the standard of care implemented in previous studies.

“Our data provide important assurances that appropriately selected patients with HIV should be offered aggressive treatment for newly diagnosed head-and-neck cancer,” the authors write. “This is particularly important because it is unlikely that a prospective trial will ever be performed in this patient population.”

Given the positive contribution of preventive antibiotics and feeding tubes, they conclude: “Gastrostomy tube placement and dental prophylaxis are recommended to minimize treatment complications.”

Search: Head-and-neck, cancer, radiation, chemotherapy, Allen Chen, side effects, oncology


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    juliar33
    brooklyn
    New York


    Deelight4u
    BROOKLYN
    New York


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.